Coexpression of cyclin D1 and alpha-internexin in oligodendroglial tumors

Brain Tumor Pathology

Volumn 32, Issue 4, 2015, Pages 261-267

  Matsumura, Nozomi ^a   Nobusawa, Sumihito ^a   Ikota, Hayato ^a   Hirato, Junko ^b   Hirose, Takanori ^c   Yokoo, Hideaki ^a   Nakazato, Yoichi ^d  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

^c HYOGO CANCER CENTER   (Japan)

^d Hidaka Hospital   (Japan)

Author keywords

Alpha internexin; Cyclin D1; Immunohistochemistry; Oligodendrocyte precursor cells; Oligodendroglioma

Indexed keywords

ALPHA INTERNEXIN; CYCLIN D1; GLIAL FIBRILLARY ACIDIC PROTEIN; KI 67 ANTIGEN; ALPHA-INTERNEXIN; CCND1 PROTEIN, HUMAN; INTERMEDIATE FILAMENT PROTEIN;

ARTICLE; ASTROCYTOMA; CANCER MORPHOLOGY; CELL PROLIFERATION; CLINICAL ARTICLE; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NERVE CELL DIFFERENTIATION; OLIGODENDROCYTE PRECURSOR CELL; OLIGODENDROGLIOMA; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; BRAIN TUMOR; CLASSIFICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

BRAIN NEOPLASMS; CYCLIN D1; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT PROTEINS; OLIGODENDROGLIOMA;

EID: 84945452197     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-015-0228-2     Document Type: Article

References (40)

1. Reifenberger G, Kros JM, Louis DN, Collins VP (2007) Oligodendroglioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) World Health Organization Classification of Tumour of the Central Nervous System, 4th edn. International Agency for Research on Cancer (IARC) Press, Lyon, pp 54–59
2. Reifenberger G, Kros JM, Louis DN, Collins VP (2007) Anaplastic oligodendroglioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) World Health Organization classification of tumour of the central nervous system, 4th edn. International Agency for Research on Cancer (IARC) Press, Lyon, pp 60–62
3. Tanaka Y, Nobusawa S, Yagi S, Ikota H, Yokoo H, Nakazato Y (2012) Anaplastic oligodendroglioma with ganglioglioma-like maturation. Brain Tumor Pathol 29:221–228
4. Perry A, Burton SS, Fuller GN, Robinson CA, Palmer CA, Resch L, Bigio EH, Gujrati M, Rosenblum MK (2010) Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall. Acta Neuropathol 120:237–252
5. Vyberg M, Ulhøi BP, Teglbjaerg PS (2007) Neuronal features of oligodendrogliomas-an ultrastructural and immunohistochemical study. Histopathology 50:887–896
6. Perry A, Scheithauer BW, Macaulay RJ, Raffel C, Roth KA, Kros JM (2002) Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications. J Neuropathol Exp Neurol 61:947–955
7. Katsetos CD, Del Valle L, Geddes JF, Aldape K, Boyd JC, Legido A, Khalili K, Perentes E, Mörk SJ (2002) Localization of the neuronal class III β-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status. J Neuropathol Exp Neurol 61:307–320
8. Hirose T, Nobusawa S, Nakazato Y, Atsushi S (2013) A case of oligodendroglioma with prominent neuronal differentiation. Hum Pathol 44:2353–2359
9. Miller RH (2002) Regulation of oligodendrocyte development in the vertebrate CNS. Prog Neurobiol 67:451–467
10. Chojnacki A, Kelly JJ, Hader W, Weiss S (2008) Distinctions between fetal and adult human platelet-derived growth factor-responsive neural precursors. Ann Neurol 64:127–142
11. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G (1993) Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7:812–821
12. Nobs L, Nestel S, Kulik A, Nitsch C, Atanasoski S (2013) Cyclin D1 is required for proliferation of Olig2-expressing progenitor cells in the injured cerebral cortex. Glia 61:1443–1455
13. Matsumoto Y, Tsunekawa Y, Nomura T, Suto F, Matsumata M, Tsuchiya S, Osumi N (2011) Differential proliferation rhythm of neural progenitor and oligodendrocyte precursor cells in the young adult hippocampus. PLoS One 6:e27628
14. Durand B, Gao FB, Raff M (1997) Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation. EMBO J 16:306–317
15. Ducray F, Crinière E, Idbaih A, Mokhtari K, Marie Y, Paris S, Navarro S, Laigle-Donadey F, Dehais C, Thillet J, Hoang-Xuan K, Delattre JY, Sanson M (2009) Alpha-Internexin expression identifies 1p19q codeleted gliomas. Neurology 72:156–161
16. Nagaishi M, Suzuki A, Nobusawa S, Yokoo H, Nakazato Y (2014) Alpha-internexin and altered CIC expression as a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion. Brain Tumor Pathol 31:257–264
17. Buckley PG, Alcock L, Heffernan J, Woods J, Brett F, Stallings RL, Farrell MA (2011) Loss of chromosome 1p/19q in oligodendroglial tumors: refinement of chromosomal critical regions and evaluation of internexin immunostaining as a surrogate marker. J Neuropathol Exp Neurol 70:177–182
18. Ducray F, Idbaih A, Reyniès A, Bièche I, Thillet J, Mokhtari K, Lair S, Marie Y, Paris S, Vidaud M, Hoang-Xuan K, Delattre O, Delattre JY, Sanson M (2008) Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile [serial online]. Mol Cancer 7:41
19. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) World health organization classification of tumour of the central nervous system, 4th edn. International Agency for Research on Cancer (IARC) Press, Lyon
20. Matsumura N, Wang Y, Nakazato Y (2014) Coexpression of glial and neuronal markers in the neurocytic rosettes of rosette-forming glioneuronal tumors. Brain Tumor Pathol 31:17–22
21. Bailey P, Bucy PC (1929) Oligodendrogliomas of the brain. J Pathol Bacteriol 32:735–751
22. Mitew S, Hay CM, Peckham H, Xiao J, Koenning M, Emery B (2014) Mechanisms regulating the development of oligodendrocytes and central nervous system myelin. Neuroscience 276:29–47
23. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715
24. Jares P, Colomer D, Campo E (2007) Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 7:750–762
25. Barnes DM, Gillett CE (1998) Cyclin D1 in breast cancer. Breast Cancer Res Treat 52:1–15
26. Shamma A, Doki Y, Shiozaki H, Tsujinaka T, Yamamoto M, Inoue M, Yano M, Monden M (2000) Cyclin D1 overexpression in esophageal dysplasia: a possible biomarker for carcinogenesis of esophageal squamous cell carcinoma. Int J Oncol 16:261–266
27. Liang S, Mu K, Wang Y, Zhou Z, Zhang J, Sheng Y, Zhang T (2013) CyclinD1, a prominent prognostic marker for endometrial diseases. Diagn Pathol 8:138
28. Arici DS, Tuncer E, Ozer H, Simek G, Koyuncu A (2009) Expression of retinoblastoma and cyclin D1 in gastric carcinoma. Neoplasma 56:63–67
29. Seiler R, Thalmann GN, Rotzer D, Perren A, Fleischmann A (2014) CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response. Mod Pathol 27:87–95
30. Liu W, Ren H, Ren J, Yin T, Hu B, Xie S, Dai Y, Wu W, Xiao Z, Yang X, Xie D (2013) The Role of EGFR/PI3 K/Akt/cyclinD1 Signaling Pathway in Acquired Middle Ear Cholesteatoma. Mediators Inflamm 651207
31. Zhao X, Song T, He Z, Tang L, Zhu Y (2010) A novel role of cyclinD1 and p16 in clinical pathology and prognosis of childhood medulloblastoma. Med Oncol 27:985–991
32. Wang J, Wang Q, Cui Y, Liu ZY, Zhao W, Wang CL, Dong Y, Hou L, Hu G, Luo C, Chen J, Lu Y (2012) Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells. J Neurooncol 106:473–484
33. Sallinen SL, Sallinen PK, Kononen JT, Syrjäkoski KM, Nupponen NN, Rantala IS, Helén PT, Helin HJ, Haapasalo HK (1999) Cyclin D1 expression in astrocytomas is associated with cell proliferation activity and patient prognosis. J Pathol 188:289–293
34. Eigenbrod S, Roeber S, Thon N, Giese A, Krieger A, Grasbon-Frodl E, Egensperger R, Tonn JC, Kreth FW, Kretzschmar HA (2011) α-Internexin in the diagnosis of oligodendroglial tumors and association with 1p/19q status. J Neuropathol Exp Neurol 70:970–978
35. Barrows BD, Rutkowski MJ, Gültekın SH, Parsa AT, Tıhan T (2012) Evidence of ambiguous differentiation and mTOR pathway dysregulation in subependymal giant cell astrocytoma. Turk Patoloji Derg 28:95–103
36. Donev K, Scheithauer BW, Rodriguez FJ, Jenkins S (2010) Expression of diagnostic neuronal markers and outcome in glioblastoma. Neuropathol Appl Neurobiol 36:411–421
37. Wharton SB, Chan KK, Whittle IR (2002) Microtubule-associated protein 2 (MAP-2) is expressed in low and high grade diffuse astrocytomas. J Clin Neurosci 9:165–169
38. Giannini C, Scheithauer BW, Lopes MB, Hirose T, Kros JM, VandenBerg SR (2002) Immunophenotype of pleomorphic xanthoastrocytoma. Am J Surg Pathol 26:479–485
39. Katsetos CD, Del Valle L, Geddes JF, Assimakopoulou M, Legido A, Boyd JC, Balin B, Parikh NA, Maraziotis T, de Chadarevian JP, Varakis JN, Matsas R, Spano A, Frankfurter A, Herman MM, Khalili K (2001) Aberrant localization of the neuronal class III beta-tubulin in astrocytomas. Arch Pathol Lab Med 125:613–624
40. Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, Jones DT, Pfister SM, Herold-Mende C, Wick W, Mueller W, Hartmann C, Paulus W, von Deimling A (2014) Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 128:551–559